{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:03:31Z","timestamp":1785528211095,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40265-025-02153-5","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T06:32:13Z","timestamp":1741069933000},"page":"585-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tasurgratinib Succinate: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2153_CR1","unstructured":"Eisai Co. Ltd. Anticancer agent TASFYGO\u00ae tablets 35 mg (tasurgratinib succinate) approved in Japan for biliary tract cancer with FGFR2 gene fusions or rearrangements [media release]. 24 Sept 2024. http:\/\/www.eisai.com."},{"key":"2153_CR2","unstructured":"Eisai Co. Ltd. Tasurgratinib (TASFYGO\u00ae): Japanese prescribing information. 2024. https:\/\/www.pmda.go.jp\/. Accessed 26 Nov 2024."},{"issue":"1","key":"2153_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12029-021-00728-5","volume":"54","author":"R Sahu","year":"2023","unstructured":"Sahu R, Sharma P, Kumar A. An insight into cholangiocarcinoma and recent advances in its treatment. J Gastrointest Cancer. 2023;54(1):213\u201326.","journal-title":"J Gastrointest Cancer"},{"issue":"11","key":"2153_CR4","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-16-0261","volume":"15","author":"S Watanabe Miyano","year":"2016","unstructured":"Watanabe Miyano S, Yamamoto Y, Kodama K, et al. E7090, a novel selective inhibitor of fibroblast growth factor receptors, displays potent antitumor activity and prolongs survival in preclinical models. Mol Cancer Ther. 2016;15(11):2630\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2153_CR5","doi-asserted-by":"publisher","first-page":"858","DOI":"10.7150\/ijms.82008","volume":"20","author":"S Conci","year":"2023","unstructured":"Conci S, Catalano G, Roman D, et al. Current role and future perspectives of immunotherapy and circulating factors in treatment of biliary tract cancers. Int J Med Sci. 2023;20(7):858\u201369.","journal-title":"Int J Med Sci"},{"issue":"e2200573","key":"2153_CR6","first-page":"1","volume":"7","author":"T Karasic","year":"2023","unstructured":"Karasic T, Eads J, Goyal L. Precision medicine and immunotherapy have arrived for cholangiocarcinoma: an overview of recent approvals and ongoing clinical trials. JCO Precis Oncol. 2023;7(e2200573):1\u201313.","journal-title":"JCO Precis Oncol"},{"issue":"3 Suppl.","key":"2153_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/JCO.2024.42.3_suppl.471","volume":"42","author":"J Furuse","year":"2024","unstructured":"Furuse J, Jiang B, Kuwahara T, et al. Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA) [abstract no. 471]. J Clin Oncol. 2024;42(3 Suppl.):471.","journal-title":"J Clin Oncol."},{"key":"2153_CR8","unstructured":"Amoy Diagnostics. AmoyDx FGFR2 break-apart FISH probe kit approved as companion diagnostic for Eisai's tasurgratinib in Japan [media release]. 4 Sept 2024. http:\/\/www.amoydiagnostics.com."},{"key":"2153_CR9","unstructured":"Amoy Diagnostics. AmoyDx and Eisai enter global diagnostic partnership agreement [media release]. 22 Nov 2019. http:\/\/www.amoydx.com."},{"issue":"6","key":"2153_CR10","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.21873\/anticanres.17046","volume":"44","author":"S Kawano","year":"2024","unstructured":"Kawano S, Kawada MI, Fukushima S, et al. Antitumor activity of tasurgratinib as an orally available FGFR1-3 inhibitor in cholangiocarcinoma models with FGFR2-fusion. Anticancer Res. 2024;44(6):2393\u2013406.","journal-title":"Anticancer Res"},{"issue":"13 Suppl","key":"2153_CR11","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1158\/1538-7445.AM2021-1414","volume":"81","author":"S Kawano","year":"2021","unstructured":"Kawano S, Fukushima S, Nishibata K, et al. Effect of E7090, an FGFR1-3 selective inhibitor, on resistance to a CDK4\/6 inhibitor and endocrine therapy in ER(+)\/HER2(-) breast cancer preclinical models [abstract no. 1414]. Cancer Res. 2021;81(13 Suppl):1414.","journal-title":"Cancer Res."},{"issue":"Suppl 1","key":"2153_CR12","first-page":"S29","volume":"211","author":"S Kawano","year":"2024","unstructured":"Kawano S, Fukushima S, Nishibata K, et al. Effect of tasurgratinib as an orally available FGFR1-3 inhibitor on resistance to a CDK4\/6 inhibitor and endocrine therapy in ER (+)\/HER2 (\u2212) breast cancer preclinical models [abstract no. PB053]. Eur J Cancer. 2024;211(Suppl 1):S29.","journal-title":"Eur J Cancer."},{"issue":"2","key":"2153_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/cas.14265","volume":"111","author":"T Koyama","year":"2020","unstructured":"Koyama T, Shimizu T, Iwasa S, et al. First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Sci. 2020;111(2):571\u20139.","journal-title":"Cancer Sci"},{"key":"2153_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcph.6104","volume":"64","author":"M Nomoto","year":"2024","unstructured":"Nomoto M, Hasunuma T, Cai C, et al. Effects of food, gastric acid reduction, and strong CYP3A induction on the pharmacokinetics of tasurgratinib, a novel selective fibroblast growth factor receptor inhibitor. J Clin Pharmacol. 2024;64:1\u201311.","journal-title":"J Clin Pharmacol."},{"issue":"16 Suppl","key":"2153_CR15","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1200\/JCO.2024.42.16_suppl.3103","volume":"42","author":"T Kogawa","year":"2024","unstructured":"Kogawa T, Yamashita T, Ishida T, et al. Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2- recurrent\/metastatic breast cancer (BC) after receiving a CDK4\/6 inhibitor [abstract no. 3103]. J Clin Oncol. 2024;42(16 Suppl):3103.","journal-title":"J Clin Oncol."},{"key":"2153_CR16","first-page":"1","volume":"116","author":"C Morizane","year":"2024","unstructured":"Morizane C, Ueno M, Ioka T, et al. Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study. Cancer Sci. 2024;116:1\u201312.","journal-title":"Cancer Sci"},{"issue":"869","key":"2153_CR17","first-page":"1","volume":"22","author":"Y Chiba","year":"2022","unstructured":"Chiba Y, Sudo K, Kojima Y, et al. A multicenter investigator-initiated phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial. BMC Cancer. 2022;22(869):1\u20137.","journal-title":"BMC Cancer"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02153-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:54:05Z","timestamp":1743303245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02153-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2153"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02153-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"24 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}